Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Introgen Therapeutics -- Ignore unavailable to you. Want to Upgrade?

To: zeta1961 who wrote (66)	5/18/2004 11:22:26 PM
From: Jibacoa	Respond to of 802

Do you have a link? It is on Page R1 of the WSJ of May 17, but I have not been looking at the WSJ on line. Bernard P.S. Re: Your question about ELN, you have to check with Michael Murphy on that. He is the one who sets the rules. I was just commenting on a rumor.

To: zeta1961 who wrote (66)	5/19/2004 11:34:19 AM
From: FiloF	Read Replies (1) \| Respond to of 802

Zeta -- Here is the relevant text from the WSJ article cited in the response to your post... <The top stock picker in the Best on the Street survey was Philip Nadeau, a 31-year-old former neurobiologist now at SG Cowen Securities Corp., a unit of Societe Generale Group of France. A "buy" rating on Introgen Therapeutics Inc., an Austin, Texas, company working on gene-based cancer treatments, yielded 223% for the part of 2003 he recommended it. Most of that gain came in early June, as Introgen reported promising early-stage data for several of its cancer treatments. Dr. Nadeau quickly switched to a "hold," capturing most of the stock's 294% bounce for the full year. He also had a big hit with Esperion Therapeutics Inc., whose shares returned 147% after he rated them a "buy" in August -- mostly because Pfizer Inc. agreed to acquire the biotech firm and its promising cardiovascular drugs at a significant premium late in the year. His tops picks for 2004 include Encysive Pharmaceuticals Inc., in Bellaire, Texas, which is expected to report results of clinical trials of a new blood-pressure drug in the second half, and San Diego-based Neurocrine Biosciences Inc., which is expected to launch a new insomnia drug with Pfizer next year.>